Med Page Today
AUGUST 31, 2024
(MedPage Today) -- LONDON -- A combination of three factors -- high-sensitivity C-reactive protein (hsCRP), LDL cholesterol, and lipoprotein(a), or lp(a) -- independently predicted cardiovascular disease over 30 years in women who were initially.
HCPLive
AUGUST 31, 2024
Rahul Aggarwal, MD, discusses the findings of a SCORED analysis examining sotagliflozin's effects based on diabetes duration.
Med Page Today
AUGUST 31, 2024
(MedPage Today) -- LONDON -- Keeping potassium levels high after cardiac surgery in hopes of preventing post-surgical atrial fibrillation (Afib) didn't work, a randomized clinical trial showed. New-onset Afib after isolated coronary artery bypass.
HCPLive
AUGUST 31, 2024
A single blood test using hsCRP, LDL-C, and Lp(a) levels can predict cardiovascular risk for women up to 30 years, emphasizing personalized care.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Med Page Today
AUGUST 31, 2024
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
HCPLive
AUGUST 31, 2024
Kenneth Mahaffey, MD, discusses FLOW trial data showing semaglutide improves cardiovascular outcomes in patients with type 2 diabetes, regardless of CKD severity.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
The New England Journal of Medicine
AUGUST 31, 2024
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual meeting.
HCPLive
AUGUST 31, 2024
RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.
Med Page Today
AUGUST 31, 2024
(MedPage Today) -- LONDON -- Despite another positive trial, controversy rages on over transcatheter edge-to-edge repair (TEER or M-TEER) in people with symptomatic heart failure (HF) and functional mitral regurgitation (MR). All three primary.
American College of Cardiology
AUGUST 31, 2024
In patients with symptomatic heart failure (HF) and moderate to severe functional mitral regurgitation (FMR), mitral transcatheter edge-to-edge repair (M-TEER) reduced cardiovascular death and heart failure (HF)-related hospitalizations with improved health status, based on results of the RESHAPE-HF2 trial presented at ESC Congress 2024 in London and simultaneously published in the New England Journal of Medicine.
Dr. S. Venkatesan MD
AUGUST 31, 2024
This ECG can help you find an answer.HR is 50/mt. Find the PR interval.It is also printed right there. What happens to PR Interval in sinus Bradycardia ? A. Remains normal B. Prolonged but within normal C. Prolonged beyond normal D. Depends on the cause of Sinus bradycardia Answer When cardiac cycle slows down, every interval must get prolonged. PR interval is no exception.
American College of Cardiology
AUGUST 31, 2024
The goal of the NOTION-3 trial was to evaluate percutaneous coronary intervention (PCI) compared with conservative therapy among patients with obstructive coronary artery disease undergoing transcatheter aortic valve implantation (TAVI).
Med Page Today
AUGUST 31, 2024
(MedPage Today) -- LONDON -- Tricuspid transcatheter edge-to-edge repair (T-TEER) improved how well patients functioned and felt without major cardiovascular events in the first academic randomized trial to affirm the pivotal trial findings.
American College of Cardiology
AUGUST 31, 2024
Continuing aspirin monotherapy for patients with previous drug-eluting stents (DES) who are undergoing low-to-intermediate risk noncardiac surgery did not significantly reduce ischemic events compared with temporarily holding all antiplatelet therapy before the surgery, according to findings from the ASSURE DES trial presented at ESC Congress 2024 in London and simultaneously published in JACC.
The American Journal of Cardiology
AUGUST 31, 2024
Publication date: Available online 30 August 2024 Source: The American Journal of Cardiology Author(s): Helene DiGregorio, Eleonora Avenatti, Rakesh Gullapelli, Kenneth Williams, Elia El Hajj, Charles Foster, Siddharth Das, Izza Shahid, Aayush Shah, Juan Nicolas, Budhaditya Bose, Kobina Hagan, Shubham Lahan, Nwabunie Nwana, Sara Butt, Zulqarnain Javed, Lily Romero Karam, Kanika Monga, Myriam Guevara, Brittany Weber
American College of Cardiology
AUGUST 31, 2024
Findings from the SWEDEGRAFT trial presented at ESC Congress 2024 in London showed no benefits to using a "no-touch" technique to harvest the saphenous vein graft during CABG compared with the conventional technique that involves stripping the vein of surrounding tissue prior to grafting.
The New England Journal of Medicine
AUGUST 31, 2024
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual meeting.
American College of Cardiology
AUGUST 31, 2024
The goal of the POPular PAUSE TAVI trial was to determine whether, in patients undergoing transcatheter aortic valve implantation (TAVI) who also take oral anticoagulation for a comorbid condition, continuation of anticoagulant therapy is noninferior to periprocedural interruption of anticoagulation with respect to major adverse cardiovascular and bleeding events.
The New England Journal of Medicine
AUGUST 31, 2024
Patients with atrial fibrillation are at high risk for stroke, and international guidelines recommend oral anticoagulant therapy. In patients with stable vascular disease without atrial fibrillation, antiplatelet therapy is recommended. However, atrial fibrillation commonly coexists with vascular diseases, such as coronary artery disease. When patients with both conditions present with.
American College of Cardiology
AUGUST 31, 2024
The goal of the RESHAPE-HF2 trial was to assess the safety and efficacy of mitral transcatheter edge-to-edge repair (M-TEER) using MitraClip among symptomatic heart failure (HF) patients with secondary mitral regurgitation (MR).
HeartRhythm
AUGUST 31, 2024
Invasive mapping of ventricular tachycardia (VT) can be time consuming and difficult to perform. A novel cloud- enabled, AI-based analysis was developed to colocalize electrical and scar VT substrate by combining computational source mapping of 12-lead ECG and wall thickness analysis using machine learning models to segment the left ventricular myocardium from CTs.
American College of Cardiology
AUGUST 31, 2024
The goal of the MATTERHORN trial was to evaluate mitral transcatheter edge-to-edge repair (M-TEER) compared with surgical mitral valve repair among patients with secondary mitral regurgitation (MR).
HeartRhythm
AUGUST 31, 2024
Early detection of structural heart disease (SHD) is paramount in cardiology. AI-based analysis of 12-lead ECGs has shown promise for detecting SHD, but further study of accuracy compared to cardiologists is needed.
American College of Cardiology
AUGUST 31, 2024
Tricuspid transcatheter edge-to-edge repair (T-TEER) significantly reduced the severity of secondary tricuspid regurgitation (TR) and improved quality of life after one year, based on findings from the Tri.fr trial presented at ESC Congress 2024 in London.
HeartRhythm
AUGUST 31, 2024
Implantable cardioverter defibrillators (ICD) are effective at terminating ventricular arrhythmias (VA), though have significant drawbacks. The opportunity to predict the onset of arrhythmia holds promise for insight into VA initiation and the opportunity to deliver therapy prior to an event. We hypothesize that novel features of intracardiac electrogram (EGM) prior to an event could be identified by deep learning to predict the onset of VA.
American College of Cardiology
AUGUST 31, 2024
How do high-sensitivity C-reactive protein (hs-CRP), low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a) [Lp(a)] levels predict cardiovascular (CV) risk over decades of time in women?
HeartRhythm
AUGUST 31, 2024
Myocardial wall thickness analysis of the cardiac CT is an emerging technique to identify arrhythmogenic tissue underlying ventricular tachycardia (VT). AI algorithms can be used to segment cardiac structures, but it is unclear how they perform in a clinical setting.
American College of Cardiology
AUGUST 31, 2024
What is the excess burden of morbidity and mortality, as determined by annual excess number of deaths and hospitalizations associated with influenza infection in patients with heart failure (HF) in Denmark?
HeartRhythm
AUGUST 31, 2024
The CommandEP system (Sentiar, Inc) is a FDA-cleared novel augmented reality system that can display a real-time, 3-dimensional (3D) electroanatomic images along with catheter locations. The system provides the user with a hands-free interface and multiple ways to interact with the 3D model. A clipping plane allows for a customizable 3D endocardial view of the cardiac chamber of interest.
American College of Cardiology
AUGUST 31, 2024
The goal of the SWEDEGRAFT trial was to determine whether harvesting a saphenous vein graft (SVG) for use in coronary artery bypass grafting (CABG) using a no-touch (NT) technique is associated with improved graft patency compared with conventional open skeletonized (COS) SVG harvesting.
HeartRhythm
AUGUST 31, 2024
Multiple reports suggest that atrial regions exhibiting either spatio-temporal dispersion (STD) or low voltage (LV) during persistent atrial fibrillation (AF) may represent driver regions.
American College of Cardiology
AUGUST 31, 2024
New late-breaking science presented at ESC Congress 2024 in London adds to the growing body of evidence looking at the potential benefits of single combination pills in managing hypertension, as well as whether evening vs. morning administration of blood pressure (BP)-lowering medications affects cardiovascular outcomes.
HeartRhythm
AUGUST 31, 2024
Influence on patient behavior— namely changing ingrained, maladaptive behaviors for those with Atrial Fibrillation (AF)— lends itself to varied methodology due to evidence-based research. Patient behavioral archetypes describe patterns exhibited by individuals in healthcare grounded on factors including socioeconomic status and attitudes surrounding change.
American College of Cardiology
AUGUST 31, 2024
The goal of the TRI.Fr trial was to assess the efficacy and safety of tricuspid transcatheter edge-to-edge repair (T-TEER) + guideline-directed medical therapy (GDMT) compared with GDMT alone among patients with symptomatic ≥ severe tricuspid regurgitation (TR).
HeartRhythm
AUGUST 31, 2024
Management of patients with cardiac implantable electronic devices (CIEDs) is challenging with many organizational aspects to consider, including for remote monitoring (RM) which is now standard of care. The 2023 HRS/EHRA/APHRS/LAHRS consensus on management of remote device clinics provided guidance, but state of current practices and performance remains unexplored.
The New England Journal of Medicine
AUGUST 31, 2024
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual meeting.
Expert insights. Personalized for you.
97 
Let's personalize your content